Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8210083 | Applied Radiation and Isotopes | 2015 | 8 Pages |
Abstract
We previously reported that 111In-labeled pertuzumab imaged trastuzumab (Herceptin)-mediated changes in HER2 expression preclinically in breast cancer tumors. To advance 111In-labeled pertuzumab to a Phase I/II clinical trial, a kit was designed for preparing this agent in a form suitable for human administration. Unit-dose kits containing pertuzumab modified with 2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid (BzDTPA) were prepared that labeled to high efficiency (>90%) with 111In and met specifications for pharmaceutical quality. The kits were stable for 4 months and the final radiopharmaceutical was stable for 24Â h. Imaging studies demonstrated high and specific uptake in HER2-positive tumors in mice using this clinical kit formulation.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Karen Lam, Deborah A. Scollard, Conrad Chan, Mark N. Levine, Raymond M. Reilly,